Cellectis Announces Conference Call to Discuss UCART19 Development Collaboration with Pfizer and Servier [EN]
Publié le 03 décembre 2015
December 3, 2015 – Cellectis (Alternext: ALCLS – Nasdaq: CLLS) will host a conference call with Pfizer Inc. (PFE) and Servier on Monday, December 7, 2015 at 8:00 a.m. Eastern Time to discuss their previously announced UCART19 development collaboration.
UCART19 is a TALEN® gene-edited allogeneic Chimeric Antigen Receptor T-Cell (CAR-T) immunotherapy developed by Cellectis. On November 19, 2015, Servier exercised its worldwide licensing option with Cellectis to UCART19 and entered into a global UCART19 license and collaboration agreement with Pfizer.
Conference Call Information
Cellectis, Pfizer and Servier management will host a conference call on Monday, December 7, 2015 at 8:00 a.m. ET to discuss UCART19 three-party collaboration.
Dial-In Numbers:
Live Participant Dial-In (Toll-Free US & Canada): 877-407-3104
Live Participant Dial-In (International): +1 201-493-6792
Replay Information:
Conference ID #: 13625168
Replay Dial-In (Toll Free US & Canada): 877-660-6853
Replay Dial-In (International): +1 201-612-7415
Expiration Date: 12/21/15
Webcast URL (Archived for 12 months):
http://cellectis.equisolvewebcast.com/12-7-UCART19